Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10207
Title: Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke.
Authors: Ly, John V;Zavala, Jorge A;Donnan, Geoffrey A
Affiliation: National Stroke Research Institute, Level 1, Neurosciences Building, Austin Health, University of Melbourne, 300 Waterdale Road, Heidleberg Heights, Victoria 3081, Australia.
Issue Date: 1-Aug-2006
Citation: Expert Opinion On Pharmacotherapy; 7(12): 1571-81
Abstract: The administration of oral aspirin within 48 h and tissue plasminogen activator within 3 h of ischaemic stroke onset remain the only treatments that have been shown to have clinical benefit. There has been much excitement about neuroprotection over the last two decades, as it may minimise the harmful effects of ischaemic neuronal damage. Although each step along the ischaemic cascade offers a potential target for therapeutic intervention, and neuroprotection has shown benefit in animal studies, this has been difficult to translate to humans. Some hope has been offered by the recent finding that the free radical scavenger NXY-059 may improve outcomes in patients presenting within 6 h of onset of ischaemic stroke. There is logic to the idea that neuroprotection may be most effective when reperfusion has occurred with thrombolysis, as the neuroprotectant will have greater access to ischaemic tissue and the opportunity is presented to minimise free radical-mediated reperfusion injury. Numerous studies in animal models support this view, but the concept has not, as yet, been rigorously tested in humans.
Internal ID Number: 16872260
URI: http://ahro.austin.org.au/austinjspui/handle/1/10207
DOI: 10.1517/14656566.7.12.1571
URL: http://www.ncbi.nlm.nih.gov/pubmed/16872260
Type: Journal Article
Subjects: Animals
Benzenesulfonates.pharmacology.therapeutic use
Brain.drug effects.pathology
Brain Ischemia.drug therapy.pathology
Drug Therapy, Combination
Fibrinolytic Agents.therapeutic use
Free Radical Scavengers.pharmacology.therapeutic use
GABA Agonists.pharmacology.therapeutic use
Humans
Neuroprotective Agents.pharmacology.therapeutic use
Nitrogen Oxides.pharmacology.therapeutic use
Piperidines.pharmacology.therapeutic use
Randomized Controlled Trials as Topic
Sodium Channel Blockers.pharmacology.therapeutic use
Stroke.drug therapy.pathology
Thiazoles.pharmacology.therapeutic use
Thrombolytic Therapy
Time Factors
Tissue Plasminogen Activator.therapeutic use
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.